Clinical Trials

28 enrolled

Esophageal Neoplasms

NCT07443397 2026-03-02

Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.

Phase 3 Recruiting

134 enrolled

Whole-Brain Radiotherapy

NCT07419932 2026-02-19

NeoLATC

Recruiting

120 enrolled

Head & Neck

Thyroid Neoplasms

NCT07396454 2026-02-09

Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib

39 enrolled

HER2-Negative Breast Cancer

NCT07398326 2026-02-09

Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer

37 enrolled

Colorectal Neoplasms

NCT06662006 2026-02-06

Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients

56 enrolled

Pancreatic Neoplasms

NCT07359053 2026-01-22

MAGNATE-S

46 enrolled

Sarcoma

NCT07330544 2026-01-09

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

118 enrolled

Breast Neoplasms

NCT06352008 2025-11-20

To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer

64 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06970145 2025-11-18

Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma

Phase 1/2 Recruiting

57 enrolled

CNS

Craniopharyngioma

NCT05582499 2025-08-22

FASCINATE-N

716 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06258642 2025-08-20

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

Phase NA Recruiting

39 enrolled

Small Cell Lung Carcinoma

NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Phase 4 Recruiting

800 enrolled

EndocrineHead & Neck

Advanced Thyroid Cancer Patients Who Received Target Therapy

NCT06874933 2025-08-12

Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)

35 enrolled

Breast Neoplasms

NCT04136535 2025-07-22

PCA

105 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06379087 2025-07-10

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07037680 2025-07-09

Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT

44 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07025174 2025-06-17

SAIB

60 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06992336 2025-05-28

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

411 enrolled

Breast Neoplasms

NCT06851247 2025-02-28

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

47 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06739395 2024-12-18

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

300 enrolled

Other solid neoplasm

Solid Tumor

NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Phase EARLY_PHASE1 Recruiting

75 enrolled

Head & Neck

Locally Advanced Thyroid Gland Carcinoma

NCT06660511 2024-10-28

Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.

5 enrolled

Gynecologic

Ovarian Cancer Recurrent

NCT06355609 2024-09-20

WUKONG-32-RW

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06348927 2024-09-19

WUKONG-32

52 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06331169 2024-08-30

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

Phase 1 Recruiting

42 enrolled

Breast Neoplasms

NCT06506838 2024-08-12

Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma

Phase 4 Recruiting

39 enrolled

Sarcoma

NCT04278222 2024-07-10

Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)

24 enrolled

Stomach Neoplasms

NCT05229003 2024-07-03

Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

44 enrolled

Colorectal Neoplasms

NCT04322617 2024-06-04

ATHENA

Phase 2/3 Recruiting

1,200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05817214 2024-04-19

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

35 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT06249750 2024-02-08

Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer

60 enrolled

Hyperthermia

NCT06211790 2024-01-18

Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma

66 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06051851 2023-09-25

RCT-PAAG

177 enrolled

Pancreatic Adenocarcinoma Metastatic

NCT06043973 2023-09-21

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Phase 3 Recruiting

98 enrolled

Advanced Non-small Cell Lung Cancer

NCT05075512 2021-10-12

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

40 enrolled